Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT06963281 is registered in ClinicalTrials.gov with Fortvita Biologics (USA)Inc. as lead sponsor.

NCT NCT06963281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06963281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Fortvita Biologics (USA)Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 29, 2025
Completion date
March 31, 2028
Enrollment
285 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors